Ocera Therapeutics, Inc.
| Nasdaq: OCRX
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of OCR-002 ornithine phenylacetate. The OCR-002 is an ammonia scavenger which is used to treat hyperammonemia and associated hepatic encephalopathy in patients with liver cirrhosis, acute liver failure and acute liver injury. The company was founded by Wu Xiaoyun and John C. Kappes on January 12, 1998 and is headquarterd in Palo Alto, CA.